Bristol-Myers Beats Celgene Investors' Drug Delay Suit
By Lauren Berg · September 30, 2024, 9:24 PM EDT
A New York federal judge on Monday tossed UMB Bank's claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying shareholders $6.4...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login